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microRNAs (miRs) are short, approximately 22-nucleotide-long non-coding RNAs involved in the control of gene expression. They guide
ribonucleoprotein complexes that effect translational repression or messenger RNA degradation to targeted messenger RNAs. miRs were
initially thought to be peculiar to the developmental regulation of the nematode worm, in which they were first described in 1993. Since
then, hundreds of different miRs have been reported in diverse organisms, and many have been implicated in the regulation of physiological
processes of adult animals. Of importance, misexpression of miRs has been uncovered as a pathogenic mechanism in several diseases. Here,
we first outline the biogenesis and mechanism of action of miRs, and then discuss their relevance to heart biology, pathology, and medicine.
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Introduction
The genomes of eukaryotes intricately encode a wide range of RNA
species. The functions of most of these RNAs have been only par-
tially elucidated or are still unknown. Alongside more common-or-
garden types such as messenger (m)—or protein-coding—RNA
and those with infrastructural roles—such as transfer and ribosomal
RNAs—two varieties of non-protein coding RNA, broadly defined
as large RNA and small RNA, have emerged over the last few
decades (for review see1). Of these,much interest has been garnered
by a group of small RNAs, called microRNA (miR), because of their
role in regulating post-transcriptional gene expression via the repres-
sion of targeted mRNAs. In fact, miRs, which are approximately 22
nucleotides long, modulate protein expression by binding to comp-
lementary sequences on mRNAs and, in doing so, target them for
translational inhibition and/or degradation. Since 1993, when they
were described for first in the nemotode worm,2,3 there has been
an acceleration in the publication of reports concerning miRs.
These have documented the presence of miRs in a variety of
animals, plants, and viruses, their role in developmental biology and
their involvement in regulating many physiological processes in the
adult organism.4 Moreover, much research is shedding light on
how the dysregulation of miRs is implicated in pathogenesis; miRs
are, therefore, potentially important clinically and might one day be
used for diagnosis, prognosis, and/or therapy. To date, over 700
miR entries have been registered for humans in the central online
database of the Wellcome Trust Sanger Institute.5
In the present review, we will first outline the biogenesis and
mechanism of action of miRs, and then discuss their relevance to
heart biology, pathology, and medicine.
The biology of microRNA
Biogenesis
Two converging pathways have been discovered for the biogenesis
of miRs in animals (Figure 1). In the first—the canonical pathway—
transcription of miR genes yields transcripts, termed primary miRs
(pri-miRs), that are up to several thousands of bases long.6
pri-miRs have a characteristic hairpin morphology, comprising a
loop and an imperfectly paired stem incorporating the mature
miR sequence on one of the strands near the loop. Transcription
of miR genes is polymerase II-dependent6 (some miRs that are
interspersed among repetitive DNA elements, however, are poly-
merase III dependent)7 and is regulated by transcription factors
(for review see8). Many miR genes are polycistronic in that they
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encode two or more stem-loops that can each be processed into
distinct mature miRs.4 As the pri-miR is transcribed, a nuclear
enzyme called Drosha—bound to a cofactor, the DiGeorge syn-
drome critical region 8 (DGCR8)—processes the pri-miRNA by
cropping the distal stem portion. Important for their recognition
in later processing, cleavage by Drosha introduces staggered cuts
on each side of the RNA stem, resulting in a 50 phosphate and a
two-nucleotide overhang at the 30 end. This produces a shorter
hairpin, called precursor miR (pre-miR).9 The pre-miRs can then
be transported to the cytoplasmic compartment of the cell by
exportin-5.10 Final processing is carried out by the miR-induced
silencing complex (miRISC)-loading complex (miRLC).11 The
miRLC is an agglomeration of proteins that removes the loop
portion of the pre-miR—by an enzyme called Dicer12—to form
a double-stranded miR duplex, strips away what is called the pas-
senger (or miRNA*) strand from the duplex to leave a mature miR,
and transfers the mature miR from Dicer to another protein of the
miRLC, called Argonaute (Ago).13 The effector of miRNA-
mediated RNA silencing is the miRISC, composed of the mature
miR attached to an Ago protein and a GW182 protein (for a
review see14).
In 2007, a second pathway was identified in which the miRs—
termed mirtrons—derive from introns that are the correct size to
form pre-miRs directly.15,16 The mirtrons are spliced out of their
host gene to form looped intermediates (or lariats) that are then
debranched and refolded into the usual stem-loop structure of
pre-miRs; mirtrons, therefore, bypass the Drosha processing step.
From here, mirtrons access the canonical biogenesis pathway
described above. To date, only a small number of mirtrons have
been found in primates.17 However, some mammalian mirtrons
might have a longer 50-tail (tailed mirtrons), so the introns that
potentially contain this type of miR might be more numerous than
first thought.18 (For an extensive review on animal miR biogenesis,
see ref. 19.)
Mechanisms of action
miR-induced silencing complexs act by first binding to sites that
seem to be predominantly present on the 30 untranslated region
Figure 1 Schematic of microRNA biogenesis and action. See text for explanation. The mature microRNA sequence is given in red. TF, tran-
scription factor; Pol, RNA polymerase II or III; Exp5, exportin 5.
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(UTR) of mRNAs. The function of the miR is to serve as the
target-recognition component of the miRISC20 because it can
bind to a complementary sequence when these are accessible.
Binding is thought to be initiated at nucleotides 2–7/8 of the
miR, the so-called seed region; the rest of the miR binds imper-
fectly, creating bulges and mismatches in the miR:mRNA heterodu-
plex (for a reviews on target recognition, see21,22). The great
advantage of this system is that a given binding-site sequence can
be present on any number of mRNAs, so a single miR sequence
is sufficient to target (and regulate) hundreds of mRNAs—which
can be part of related processes or pathways—contempora-
neously; moreover, in order to target a different set of mRNAs,
only the miR needs to be changed while the protein components
of the miRISC can remain the same. The efficacy of the system can
be regulated through the presence of multiple target sites on a
given mRNA’s 30UTR, enabling a number of miRs to bind coopera-
tively and, thus, effect a stronger action.
Once locked on an mRNA, the proteins making up the miRISC
promote downregulation of the protein the mRNA encodes (for
extensive reviews, read23,24). A number of animal miRs have
been reported to promote gene silencing through mRNA degra-
dation.23,24 However, it has been speculated that translational
repression is the default mechanism of miR-mediated repression
of gene expression:25 whether this occurs at the initiation or a
post-initiation step is still being debated. In addition, a few
reports have described activation of translation by miRs.26–29
Further studies are needed to ascertain whether the various find-
ings are due to distinct mechanisms, diverse moments of an initial
miR-mediated event or experimental artefacts.
Targets of microRNA
Many programs are available online for the prediction of individual
targets of miRs (for reviews, see30,31). However, the identification
of bona fide targets in animals remains problematic because animal
miRs bind to mRNA with imperfect complementarity and we still
have anonly partial understanding of howbinding sites are recognized.
Thus, somebioinformatically predicted targets turnout tobe false and
others are overlooked altogether. Experimental validation of targets
is, therefore, an important step in defining the functions of individual
miRs (for review, see32). Unfortunately, the identification of targets
within a living system is not without its own problems too, and the
data obtained need to be evaluated with care. For example, the use
of an artificial reporter constructed with a large number of binding
sites and without the other features that probably affect target recog-
nition (such as tertiary mRNA structure and binding sites for other
miRs and proteins)4 can produce an exaggerated, not necessarily
physiologic, outcome (e.g. ,30-fold change), whereas the effect of
the cognate miR on the expression of a given native protein may in
reality be relatively quite small (e.g. less than four-fold change).33
Also, because a given miR might target multiple mRNAs to produce
a discernible phenotype, an effect studied on any single protein
might be relatively unimportant on itsown.33,34Moreover, targets vali-
dated through the overexpression of ectopically introduced miRs are
not necessarily authentic biological targets because of, for example,
the presence of differentially expressed UTR-binding proteins that
block the formation of the heteroduplex in another cell type.34
microRNA and the heart
Cardiac-expressed microRNAs
Of the thousands of miRs described to date in humans and other
animals, many exhibit tissue-specific patterns of expression.35
Because of their ability to target classes of mRNAs that direct cell
proliferation, differentiation, and programmed death,36 tissue-
specific miR expression gave rise to the idea that they would play
a major role in tissue differentiation and organ development.
Although this was shown to be correct in specific instances, i.e. in
muscle, miR-1 and miR-133a are co-expressed in response to
several myocyte differentiation factors,37,38 it has not held up as a
general rule. Instead, there appear to be !150–200
cardiac-expressed miRs, many of which are dynamically regulated
in response to acute cardiac stress, and in some instances during
the long-term compensatory response of the heart to chronic
injury or haemodynamic overload. Thus, there is increasing evidence
that modulated miR expression is an important part of the acute
stress-response mechanism of the heart, and that this additional
level of regulatory complexity contributes both to cardiac homeo-
stasis in health, and to myocardial pathology in disease.
Of the miRs expressed in the heart, some are either enriched in
or specific to this organ. miR-1, miR-133, miR-206, and miR-208
have been found to be particularly important for muscle. The
miR-1 family comprises the miR-1 subfamily and miR-206, the
latter expressed in skeletal but not cardiac muscle. The miR-1 sub-
family consists of two identical transcripts, miR-1-1 and miR-1-2,
which are differentiated by the addition of the numerical suffix
because they are encoded on different chromosomes (ch2 and
ch18, respectively). The miR-1 members are expressed from bicis-
tronic units together with members of the miR-133 family, which
comprises miR-133a-1, miR-133a-2 and miR-133b (the lettered
suffix denotes that the miRs differ at only one or two positions).
Only one miR, miR-208, is acknowledged as being cardiac-specific.
It is encoded in an intron of the alpha myosin heavy chain gene.
Other miRs that might be potential cardiac-enriched miRs
include miR-128, miR-302, miR-367, and miR-499.39 The most
recent data on the miR profile of adult mouse heart, determined
by sophisticated and highly sensitive RNA resequencing, is
reported by Rao et al.40
Experimental validation of cardiovascular-related miR targets has
only recently got under way, and only a few targets have been
described as pertinent to the cardiomyocyte to date: these have
been reported to be involved in the regulation of various aspects
such as heart development,41 hypertrophic cardiac growth,42–47
electrophysiology,48–50 apoptosis,51–54 and metabolism55
(Table 1). Moreover, miRs and relative targets are being uncovered
for the other cells making up the cardiovascular system, such as
fibroblasts,56–59 endothelial cells,60 and smooth muscle cells,61–65
which cannot be overlooked when studying the physiology of the
cardiovascular system or its response to stress.
The importance of microRNA biogenesis
to the developing and adult heart
Dicer splicing of mature miRs from pre-miRs is the penultimate
step of miR biogenesis, and is common to all miRs. For this
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Table 1 Cardiomyocyte-expressed microRNAs with experimentally verified targets
microRNA Setting (modela) Dysregulation Target(s) Effect of miR on
miR-142 Hypertrophy (TAC); iCMP (h) Down Cdk9, Rheb, RasGAP, Fibronectin Hypertrophy (2)
miR-147 Hypertrophy (TAC); acromegaly (h) Down IGF1 Hypertrophy (2)
miR-151 Oxidative stress (H9c2) Up HSP60, HSP70 Apoptosis (þ)
miR-154 Oxidative stress (H9c2) Up Bcl-2 Apoptosis (þ)
miR-148 Various — Sarcolemmal channel protein mRNAs Electrophysiology
miR-150 miR overexpression (ARVC) Up B56a Sarcoplasmic reticulum Ca2þ release (þ)
miR-1-237 miR deletion (miR-1-2 KO) Down Irx Repolarization (Ito)
miR-2152 Oxidative stress (NRVC) Up PDCD4 Apoptosis (2)
miR-23a44 Hypertrophy (NRVC) Up MuRF1 Hypertrophy (þ)
miR-30c56 Hypertrophy (Ren2); AS (h) Down CTGF Fibrosis (2)
miR-13345 Hypertrophy (TAC) (training) (Akt-Tg); iCMP (h) Down Rho-A, NELF, Cdc42 Hypertrophy (2)
miR-13351 miR Overexpression (H9c2) Up Caspase9 Apoptosis (2)
miR-13348 Various — Sarcolemmal channel protein mRNAs Electrophysiology
miR-13356 Hypertrophy (Ren2); AS (h) Down CTGF Fibrosis (2)
miR-13355 miR downexpression (ARVC); hypertension (Dahl rats) Down KLF15 Glucose uptake (þ)
miR-20846 Hypertrophy (miR-208 KO) Down THRAP-1 Contraction (þ)
miR-20849 miR overexpression (Tg) Up THRAP-1; Myostatin Hypertrophy (þ)
miR-32053 Ischemia/reperfusion (rat) Down HSP20 Apoptosis (þ)
TAC, transverse aortic constriction; iCMP, idiopathic cardiomyopathy; h, human; CaN calcineurin; Tg, transgenic; H9c2, rat embryonic ventricle-cell line; A/NRVC, adult/neonatal rat ventricular cardiomyocytes; KO, knockout; Ren2,
homozygous rat model of hypertension-induced heart failure; AS, aortic stenosis; (2), anti; (þ), pro.
aMouse if not otherwise stated.
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reason, experimental manipulation of Dicer expression has
afforded an opportunity to examine the consequences of global
miR perturbations on cardiac formation and function. The results
provide insight into the distinct roles of regulated miR expression
during embryonic development and in the physiologically stressed
adult heart.
Sophisticated molecular techniques have been employed to
ablate the Dicer gene from mouse hearts at various times during
the life of the organism. Cardiac-specific Dicer ablation is necessary
because somatic Dicer ablation produces early embryonic lethality
due to an apparent defect in gastrulation.66 Accordingly, mice car-
rying floxed Dicer genes have been bred to three different cardiac-
specific Cre mice to specifically ablate Dicer from cardiomyocytes
at different times or under different experimental conditions: early
in the developing heart (Nkx-2.5 Cre)37; shortly after birth
(aMHC-Cre)67; and either in 3-week-old or adult mice
(tamoxifen-inducible aMHC Cre).68 Specific details of the resulting
phenotypes can be found in the respective reports and have
recently been summarized.69 Because Dicer deletion may have
effects that are not specifically a consequence of interfering with
miR biogenesis, the parallel approach of conditionally ablating
DGCR8, also important for miR production, was recently
employed.40 In this case, the use of a muscle-specific Cre driver
that is most active after birth to ablate DGCR-8 again resulted in
progressive cardiomyopathy. The importance of these collective
findings is that interference with miR biogenesis at any time from
very early in heart development to the fully developed adult
heart results in catastrophic cardiac failure, with induction of
pathological cardiac genes, loss of normal sarcomeric organization,
and cardiomyocyte hypertrophy and/or apoptosis. These results
support a critical role for miRs not only in growing or developing
hearts but also in maintaining normal cardiac homeostasis. Thus, it
has been important to examine the pattern of miR expression and
regulation in adult heart disease, as described in what follows.
microRNA and heart pathology
microRNA signatures in experimental heart disease
Most of the existing in vivo basic research describing patterns of
cardiac miR expression, and elucidating their individual effects,
has been performed using mice. Mice are excellent models
because their genes (and miRs) are readily manipulated, the
anatomy of the cardiovascular system is similar to that of
humans, routine physiological analysis is possible using echocardio-
graphy, magnetic resonance imaging, and invasive catheterization-
based haemodynamic measurements, and the time course of
cardiac disease progression is compressed in comparison with
larger animal models.
There are two broad classes of models of experimental murine
heart disease: genetic and physiological. In genetic models, a critical
causal factor is overexpressed under control of the promoter from
a cardiac-specific gene, typically the aMHC promoter. Because
expression of the transgenic factor is driven in a cardiomyocyte-
specific manner, the molecular phenotype (including mRNA and
miR expression profiles) is generally assumed to be the direct con-
sequence of the transgene rather than of a collateral systemic
event. Thus, genetic mouse models have the advantage of revealing car-
diomyocyte autonomous changes. And as with conventional
hypertrophy and heart failure, different genetic models produce
different ‘flavours’ of disease. In miR profiling studies, there are
substantial data from two genetic models: Akt transgenic mice
that produce ‘physiological hypertrophy’, similar to a trained ath-
lete’s heart that does not progress to failure;45 and calcineurin
(CaN) transgenic mice, which produce ‘pathological hypertrophy’
that more resembles pressure overload hypertrophy and that
can progress to heart failure.70 There are also data from pressure
overload hypertrophy that occurs in response to surgical banding
of the aorta,42,71,72 and myocardial infarction produced by surgical
ligation of the left anterior descending coronary artery.57 These
models have the advantage of being more relevant to human
pressure overload and myocardial infarction, but the data
interpretation can be confounded by non-cardiac effects of the
physiological manipulations.
miRs reported to be up- or down-regulated in the various
mouse models described earlier are listed in Table 2. There are a
few notes of caution before broad generalizations can be derived
from these cumulative expression profiling data. First, the data
need to be interpreted in the context of evolving platforms for
assaying miR levels, and the rapid expansion of recognized miRs.
Older studies assayed a limited number of miRs compared with
more recent studies. Second, a cardiac-expressed miR is not
necessarily a cardiomyocyte-expressed miR. Interventions, such
as pressure overloading and myocardial infarction that affect the
entire heart including interstitial cells, the coronary macro- and
micro-vasculature and resident or migratory inflammatory cells,
will not produce the same RNA expression signatures as genetic
manipulations that directly affect only cardiomyocytes. Finally,
genetic models are artificial and even experimental pressure over-
loading and myocardial infarction are acute interventions that do
not precisely mimic the chronically progressive conditions seen
in human diseases with the same names. Thus, the miR expression
profiling data from mouse models identify a large number of miRs
that are expressed in the heart at relatively high levels, and a subset
of these that are subject to dynamic regulation under conditions of
myocardial stress or injury. If associations between these exper-
imentally regulated miRs and their human counterparts were
also observed in clinical heart disease, the implication would be
that cross-species conservation of regulation would more strongly
suggest biological relevance.
microRNA signatures in clinical heart failure
As with mouse cardiac models, microarrays have been used by a
number of groups to profile miR expression signatures in human
heart disease, most commonly dilated or ischaemic cardiomyo-
pathies. The initial report of miR profiling in human heart
disease was by Thum et al., who compared mRNA and miR
expression signatures from four non-failing and six failing
hearts.73 The Ambion miR microarrays contained probe sets
for 384 miRs. The authors noted significant (defined as P,
0.05, .1.5-fold increase or decrease) upregulation of 67 miRs,
with downregulation of 43 miRs, in the failing vs. control
hearts (Table 3). The miRNA expression signature was similar
to that of (n ¼ 6) fetal hearts, suggesting that both mRNA and
miR expression in heart failure partially recapitulates that of
the embryonic heart.
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In a substantially larger clinical study published just months later,
Ikeda et al.74 described the miR profiles of human dilated cardio-
myopathy (n ¼ 25), ischaemic cardiomyopathy (n ¼ 19), and
pressure overload hypertrophy (aortic stenosis, n ¼ 13), com-
pared with that of 10 normal hearts. Their assay measured levels
of 428 individual miRs using a high-throughput bead-based plat-
form75 that detected 87 cardiac-expressed miRs, 43 of which
were regulated in at least one of the disease groups (P, 0.05,
FDR , 5%) (Table 3). Importantly, the miR expression profile
appeared to be distinguishable between disease groups, and
within the primary data set the miR signature was able to
predict the diagnosis with an accuracy rate that approached 70%.
A similarly designed study by Sucharov et al.76 compared miR
expression in five ischaemic and five non-ischaemic cardiomyo-
pathic hearts, compared with six non-failing hearts. The assay
used a microarray containing probes for 470 miRs. Thirty-three
miRs were reported as regulated in either ischaemic and/or non-
ischaemic cardiomyopathic hearts (P, 0.1) (Table 3), several of
which were shown to have measurable effects in cultured neonatal
rat ventricular cardiomyocytes. Naga Prasad et al.77 used a custom
microarray to identify eight miRs (seven of which had been pre-
viously identified in human or mouse heart failure) that were upre-
gulated in 50 heart failure cardiac samples, compared with twenty
non-failing specimens, and independently validated the associations
in 20 dilated cardiomyopathy and 10 non-failing samples. Taken
together, these studies support the idea that miR regulation may
be sufficiently distinct in different forms of cardiac injury to be
able to discriminate between heart failure of ischaemic vs. non-
ischaemic aetiology.
In a recent study, Matkovich et al.78 examined whether miRs that
were regulated in heart failure would be normalized by left-
ventricular assist device (LVAD) therapy, i.e. they measured the
sensitivity of miR dynamism to functional changes in the failing
heart. miR and mRNA expression profiles were generated for 17
cardiomyopathic hearts not treated with LVADs, 10 hearts on
treatment with LVADs and 11 non-failing control hearts. The Invi-
trogen miR array contained probe sets for 467 miRs, of which 81
were confidently expressed in hearts. Of these, 28 were upregu-
lated in cardiomyopathic hearts (P, 0.001, greater than two-fold
increase), with three others showing strong trends (P, 0.01)
(Table 3). The most interesting finding was that 20 of the 28 upre-
gulated miRs were fully normalized in LVAD-supported hearts, and
the other eight decreased towards normal. A limited qPCR study
of four miRs also found that LVAD treatment normalized abnormal
expression, but suggested that this effect was more pronounced in
ischaemic cardiomyopathy.79 The remarkable sensitivity of the miR
signature to biomechanical support, which is known to favourably
effect both cardiac performance and remodelling, parallels regu-
lated expression of Dicer, the critical enzyme for processing to
mature miRs (see above). Dicer levels are decreased in human
heart failure, but normalized by LVAD treatment.67 It is possible
that acute regulation of Dicer expression in human heart failure
plays a role in the dynamic expression of members of the heart
failure miR program, but mechanistic linkage between the two pro-
cesses has not yet been established.
microRNAs in myocardial ischaemia and vascular diseases
miR plays an important role in regulating endothelial homeostasis,
and angiogenesis in vivo. For example, targeted deletion of the
endothelial cell-restricted miR miR-126 causes leaking of vessels,
haemorrhaging and partial embryonic lethality, due to a loss of vas-
cular integrity and defects in endothelial cell proliferation,
migration, and angiogenesis. Mutant surviving mice display defec-
tive cardiac neovascularization following myocardial infarction. A
link was demonstrated between miR-126 and VEGF and FGF in
that it increases the pro-angiogenic effects of these two cyto-
kines.80,81 Evidence of the potentially relevant role of miRs in vas-
cular diseases was also provided by the miR-17approximately92
cluster, which is highly expressed in endothelial cells; miR-92a, a
component of this cluster, controls the growth of new blood
vessels.82 Forced overexpression of miR-92a in endothelial cells
blocked angiogenesis in vitro and in vivo. In mouse models of limb
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Table 2 microRNA expression and regulation in
experimental models of heart failure
Upregulated microRNAs
miR-10a57 miR-92b57 miR-199a42,70 miR-35257
miR-10b57,70 miR-10342,57 miR-199a*42,70 miR-36557
miR-15b42,57 miR-106a72 miR-199a-3p57 miR-37957
miR-1657 miR-10742,57 miR-199a-5p57 miR-48357
miR-17-5p72 miR-125b42,70,72 miR-199b42 miR-49757
miR-18b72 miR-12670 miR-199b*57 miR-574-5p57
miR-19a67 miR-12742,57 miR-200a72 miR-63857
miR-19b72 miR-13257 miR-20872 miR-70557
miR-20b72 miR-14042,72 miR-21070,72 miR-71157
miR-2142,57,70,72 miR-140*42,57 miR-21170 miR-73957
miR-23a42,70 miR-142-3p72 miR-21442,57,70 miR-76257
miR-23b42,70 miR-146a57 miR-21770 miR-92357
miR-2442,70 miR-146b57 miR-21857,70 let-7b42,57
miR-2570 miR-15372 miR-22142,57,72 let-7c42
miR-26b57 miR-15470 mR-22242,57,72 let-7d57
miR-27a42,70 miR-15557 miR-22357 let-7e57
miR-27b42,70 miR-18472 miR-33070 let-7g57
miR-3142 miR-19542,70 miR-335-5p57 let-7h57
miR-34a57 miR-199*57 miR-35142,57,70 let-7j57
Downregulated microRNAs
miR-142 miR-30a-3p42 miR-9370 miR-15542
miR-10a42 miR-30a-5p42 miR-133a70 miR-181b70
miR-10b42 miR-30b42,72 miR-133b70 miR-18542
miR-26a42 miR-30c42,72 miR-13942 miR-19442
miR-26b42 miR-30d42 miR-14942 miR-21842
miR-29a42 miR-30e42,70 mR-15042,70,72 miR-37842
miR-29c42,70 miR-30e*42 miR-15142 let-7d*42
Non-regulated microRNAs
miR-15a71 miR-125a71 miR-148a71 miR-45171
miR-2271 miR-126-3p71 miR-15271 miR-48671
miR-29b71 miR-126-5p71 miR-181a71 let-7a71
miR-9871 miR-14371 miR-19171 let-7f71
miR-99a71 miR-14571 miR-34171 let-7i71
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ischaemia and myocardial infarction, administration of an antago-
mir designed to inhibit miR-92a led to enhanced blood vessel
growth and functional recovery of damaged tissue. miR-92a
appears to target mRNAs corresponding to several pro-angiogenic
proteins, including the integrin subunit alpha5. Thus, miR-92a may
serve as a valuable therapeutic target in the setting of ischaemic
disease.83
The role of miRs in cardiovascular diseases has been recently
further confirmed by studying their expression in the smooth
muscle cell (SMC) compartment. For example, the miR-143/145
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Table 3 microRNA expression and regulation in human heart disease
Upregulated miRNAs
miR-177 miR-125b74,77 hsa-miR-29a73 hsa-miR-525-AS73
miR-15a77 miR-12677 hsa-miR-3273 let-7b74
miR-15b74 miR-130a77 hsa-miR-34b73 let-7c74
miR-1677 miR-133a77 hsa-miR-10076 let-7e74
miR-2177 miR-133b77 hsa-miR-125a73 let-7f77
miR-2277 miR-140*74 hsa-miR-125b76 let-7g77
miR-23a74,77 miR-14377 hsa-miR-126-AS73 let-7i77
miR-2474,77 miR-14574 hsa-miR-130a73 hsa-let-7a73
miR-26a77 miR-181a74 hsa-miR-13273 hsa-let-7c73
miR-26b76,77 miR-19174 hsa-miR-181b76 hsa-let-7d73
miR-27a74,77 miR-19574,77 hsa-miR-19576 hsa-let-7e73
miR-27b74,77 miR-199a*74 hsa-miR-19976 mmu-miR-17-3p73
miR-2876 miR-199a-3p77 hsa-miR-21273 mmu-miR-21573
miR-29a77 miR-21474 hsa-miR-21373 mmu-miR-292-3p73
miR-29b77 miR-32074 hsa-miR-302a73 mmu-miR-29573
miR-30a-5p77 mR-34274,76 hsa-miR-32073 mmu-miR-29773
miR-30b77 miR-37877 hsa-miR-36573 mmu-miR-32273
miR-30c77 miR-423*74 hsa-miR-37273 mmu-miR-33073
miR-30d77 miR-49977 hsa-miR-37373 mo-miR-29773
miR-9374 miR-63877 hsa-miR-38273 mo-miR-33373
miR-99b74 hsa-miR-173 hsa-miR-42373
miR-10074 hsa-miR-2173 hsa-miR-42473
mR-10374,77 hsa-miR-23a76 hsa-miR-42973
Downregulated miRNAs
miR-174,76 miR-12674 hsa-miR-30c76 hsa-miR-48673
miR-10a74 miR-126*74 hsa-miR-9276 hsa-miR-49473
miR-17-5p74 miR-22274,76 hsa-miR-133a76 hsa-miR-515-5p73
miR-19a74 miR-22476 hsa-miR-133b76 hsa-miR-520d-AS73
miR-19b74 miR-37474 hsa-miR-13976 hsa-miR-59476
miR-20a74 miR-45174 hsa-miR-15076 let-7a76
miR-20b74 miR-48476 hsa-miR-18273 let-7c76
miR-26b74 miR-49974 hsa-miR-19776 let-7d76
miR-2874 hsa-miR-10b76 hsa-miR-22176 let-7f76
miR-30e-5p74 hsa-miR-20a76 hsa-miR-422b74,76
miR-10174 hsa-miR-2276 hsa-miR-452-AS73
miR-106a74 hsa-miR-30a-5p73 hsa-miR-48376
Non-regulated miRNAs
miR-23b77 miR-148a77 miR-20877 miR-45277
miR-29c77 miR-15177 miR-22177 miR-487b77
miR-30a-3p77 miR-15277 miR-22377 miR-520h77
miR-9877 miR-18577 miR-324-5p77 miR-65277
miR-99a77 miR-18877 miR-33777 miR-66377
miR-10777 miR-19877 miR-36177
miR-125a77 miR-199a-5p77 miR-37777
miR-146a77 miR-199b77 miR-422a77
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cluster has been demonstrated to be specifically expressed in
SMCs;61–65 their expression is controlled by SRF and is decreased
during acute (re-stenosis) or chronic (atherosclerosis) stress.
Knockout of miR-143/145 induces defects in SMC terminal differ-
entiation which is reflected by a decreased capacity for vasocon-
striction after vasopressor challenge.61,63,64 The cytoskeletal
apparatus is particularly affected by the knockout of miR-143/
145. Smooth muscle cell proliferation and migration seem also
to be regulated by the miR-143/145 cluster.61–65
The tenuous relationship between mRNA
and microRNA signatures
Given that miRs exert their effects by directing specific target
mRNAs to miRISCs for degradation, it has been widely assumed
that comparative miR and mRNA profiling informed by bioinfor-
matics identification of consensus miR binding sequences would
link regulated miRs with their relevant mRNA targets. However,
this has not generally been the case. The two human studies in
which comprehensive mRNA and miR signatures were obtained
in the same clinical cardiac samples failed to reveal clear reciprocal
relationships between upregulated miRs and downregulation of
their putative mRNA targets.73,77 Nevertheless, miRs have impor-
tant pathophysiological effects on cardiomyocytes, as shown by in
vitro and in vivo manipulation.45,70 We believe that the answer is
suggested by accumulating data suggesting the major effect of
miRs in mammalian systems might not be mRNA destabilization,
but rather translational suppression.33 If this is the case, mRNA
profiling can identify only those mRNA targets of miRs that are,
directly or indirectly, destabilized, and will miss the majority of
bona fide targets that undergo translational inhibition without
altering mRNA levels. This situation requires a different approach
to connect specific miRs and their mRNA targets, such as profiling
mRNAs from the RISCs of cells or model organisms in which
specific miRs are overexpressed.84
Implications of microRNA
for clinical practice
From mRNA to microRNA expression
profiling in cardiac disease
A mechanistic role for altered mRNA expression levels in heart
disease has been recognized for many years.85 A few hallmark
genes are regulated in virtually every clinical and experimental
model of cardiac hypertrophy and/or heart failure. The most sen-
sitive transcriptional marker for heart failure is increased cardio-
myocyte expression of mRNAs for the atrial and brain
natriuretic peptides, ANF and BNP. On the other hand, cardio-
myocyte hypertrophy is indicated by a redistribution of myosin
heavy chain isoform mRNA from alpha (a-MHC) to beta
(b-MHC). Transcriptional upregulation of natriuretic peptides
and b-MHC is observed in cultured cardiac myocytes induced to
undergo hypertrophy, in genetic rodent models of cardiac hyper-
trophy and cardiomyopathy, in rabbit, dog, and porcine experimen-
tal models of surgically induced cardiac disorders, and in the
analogous human diseases. Thus, a conserved transcriptional
signature for heart disease appears to be a nearly universal
response, and in many instances the individual regulated transcripts
have been mechanistically connected to specific pathological fea-
tures of hypertrophied and failing myocardium.86 However,
because end-stage cardiomyopathy combines features of heart
failure with cardiomyocyte hypertrophy, ANP/BNP and b-MHC
are typically increased together with many other members of
the so-called ‘fetal gene program’ in fully developed adult cardio-
myopathies. Combinatorial regulation of many mRNAs in cardiac
disease diminishes the specificity of the response for a particular
condition. For example upregulation of ANP along with b-MHC
in a cardiomyopathic heart does not provide data as to whether
cardiomyocyte hypertrophy led to heart failure, as in severe hyper-
tension, or is part of a compensatory response to primary myocar-
dial damage, as after myocardial infarction. Furthermore, since
heart failure is the common terminal condition that results from
irreparable myocardial damage of any cause, the transcriptional
profile of late heart failure provides little insight into specific aetiol-
ogy (ischaemic, viral, alcoholic) or information about likely progno-
sis.87 For these reasons, mRNA profiling has not transitioned from
the research laboratory to routine clinical practice.88 There is,
however, tremendous interest in determining whether dynamic
regulation of cardiac-expressed miRs could prove more useful
than mRNA profiling as a molecular signature for specific cardiac
syndromes. With the development of faster and cheaper high-
throughput technologies, this could be a particularly exciting pro-
spect for diagnosis and prognostication in cardiology.
Modulation of dysregulated microRNAs
That the misexpression of an miR could be involved in a patho-
genic mechanism was reported first for leukaemia89 and then for
many other pathologies.36 This has spurred the setting up of
biotech companies with the aim of developing miR-based
drugs.90 The therapeutic strategy would be directed at normalizing
miR expression, silencing those that become inappropriately over-
expressed or replacing those that become downregulated
(Figure 2A).
Administration of a single-stranded oligonucleotide that is anti-
sense to a disease-upregulated miR (anti-miR oligonucleotides or
AMOs), for example, could act as a competitive inhibitor and
determine the upregulation of sets of proteins. Chemical modifi-
cation is necessary to improve the pharmacokinetic properties of
oligonucleotide (for review see91). One modification involves con-
jugation with cholesterol, which enhances transport across cell
membranes, to form so called antagomiRs:92 these have been
used successfully in in vivo models to inhibit miRs and produce a
relevant pharmacological effect on the heart.45,53,58 Two or
more identical miR-binding sites can be synthesized in series in
order to sequestrate a larger number of miRs (erasers93 or
sponges94). If these are constructed from partially complementary
sequences harbouring a seed sequence, they can be used to
sequester all the related miRs of an miR family. Moreover,
sponges have been synthesized that target different miRs contem-
poraneously: these multiple-target AMOs (MTg-AMOs) were
shown to be more effective than using mixtures of AMOs targeting
individual miRs separately.95 On the other hand, miRs that have
been downregulated by disease might be pharmacologically
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re-expressed via the introduction of precursors, or of their coding
sequences, that co-opt the miR biosynthetic machinery.
The potential advantage of targeting, or artificially re-expressing,
miRs directly lies in the potential to restore the expression of hun-
dreds of dysregulated mRNAs to their pre-pathological level in one
go and, in doing so, hopefully reverse disease. However, miR-based
approaches might also be taken advantage of to affect only one
target should this be deemed desirable (Figure 2B). By identifying
an accessible and suitably long sequence on the 30UTR that is
unique to the gene of interest, an oligonucleotide precursor can
Figure 2 Schematic overview of strategies used to alter microRNA expression. (A) Cells express a microRNA profile that can become
altered with disease. Antisense oligonucleotides, such as antagomirs, sponges, and erasers (in red) can capture microRNAs for knockdown
or sequestrate inappropriately overexpressed microRNAs, whereas artificially introduced microRNAs (in red) can be used to overexpress
microRNAs or, potentially, to replace expression of downregulated ones. These strategies have the potential to affect large numbers of differ-
ent targets (for simplicity, only one target mRNA per microRNA is represented). (B) Masks and gene-specific microRNA mimics (in red) can be
used to affect single targets specifically (mRNAs in different shades of blue represent a set affected by a given microRNA).
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be synthesized to have a sequence that binds only to a given
mRNA and to effect translation inhibition only of this specific
mRNA (gene-specific miR mimics).96 A sequence can also be gen-
erated in such a way as to occupy an miR-binding site of a single
cognate mRNA without being first incorporated into an miRISC:
these miR masks specifically impede the action of the miRISC on
that specific mRNA without affecting any actions on other
cognate mRNAs.96
Conclusions
Our understanding of miR has come a long way in a short period of
time. miRs have emerged as important controllers of gene
expression, as pathogenic triggers when misexpressed and as
potential targets of therapeutic interventions. However, the
biology of miR is complex and has not been fully clarified: it is
probable that not all miRs have been discovered yet and, even if
they have been, we are far from having a definite picture of the
mRNAs they regulate; how miRs interact with transcription
factors and how they themselves are regulated, modified, and
degraded are still being defined. Moreover, miRs have been
linked to gene silencing at the transcriptional level97 and other,
as yet unknown, functions may still be discovered.
Before miRs become useful clinically for heart disease diagnosis/
prognosis, it will be necessary to obtain standardized and detailed
expression profiles of healthy and diseased tissue. A parallel
advance in procedures capable of analysing large numbers of
miRs quickly and economically will be needed too. The use of
miRs for therapy is also not still without problems. We have
given only a brief outline of the techniques that can be used at
the moment to modulate miR expression. Many of the above strat-
egies have not been extensively tested yet in in vivo heart disease
models, let alone in humans. They remain experimental techniques
useful for the study of miRs. Moreover, the currently available anti-
sense approaches—to transiently deliver preformed, short RNA
sequences—or gene therapy technologies—to stably introduce
sequences that encode miR-precursor transcripts—will need to
be developed and adapted. Furthermore, because of the multiple
miRs involved, cardiovascular diseases may turn out to be more
problematical to treat than, for example, tumours that can arise
from the misexpression of single oncogenic miRs. Therefore,
hurdles, such as better understanding of the function of individual
miRs and adequate, efficient, safe, and standardized delivery of oli-
gonucleotide sequences to the heart parenchyma remain to be
overcome. With these advances, miR-based diagnosis and
therapy will, hopefully, become a reality for clinical cardiology.
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